AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02228408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo titration will mimic titration of active study arm
Trial: NCT05155839
Drug: MRG001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated intravenously
Trial: NCT01251991
Drug: Psyllium husks
RxNorm normalized name: Psyllium 500 MG Oral Capsule [PSYLLIUM HUSKS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension, oral use, two daily dosages consisting of 5 grams each
Trial: NCT00227409
Drug: calcium disodium EDTA (edetate calcium disodium)
RxNorm normalized name: DISODIUM EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00931606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to 4 subcutaneous doses of placebo given once every 28 days
Trial: NCT02378688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00744692
Drug: Reduced Intensity Conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03113994
Drug: Rosuvastatin Calcium
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg Rosuvastatin, daily for 12 months
Trial: NCT03113994
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, daily for 12 months
Trial: NCT01512693
Drug: MK-0822
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
Trial: NCT01620593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of placebo after castration, blinded to the patient and the study team.
Trial: NCT03595189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-hour single intravenous administration
Trial: NCT00741260
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine orally on days 1-14 of each 21 day cycle
Trial: NCT05533073
Drug: A2: Etoricoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arcoxia®, Schering Plough S.A. de C.V. A2: Pharmaceutical Form: Tablet Formula: 90 mg Dosage: 1 tablet of 90 mg Administration way: oral
Trial: NCT00035477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
Trial: NCT01671891
Drug: capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
Trial: NCT03355053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: From the package insert: 0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is produced by Pfizer Inc, NY, Ny (formerly Hospira). It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+ ) 154 mEq; chloride (Cl- ) 154 mEq. The osmolarity is 308 mOsmol/L (calc.). The pH is 5.6 (4.5 to 7.0). This solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection. When smaller doses are required, the unused portion should be discarded. 0.9% Sodium Chloride Injection, USP is a parenteral fluid and electrolyte replenisher. Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water. Water for Injection, USP is chemically designated H2O.
Trial: NCT02732249
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given 30 min after morning and evening meals
Trial: NCT00351806
Drug: Erigeron breviscapus injection
RxNorm normalized name: ERIGERON CANADENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00033371
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given 400 mg PO twice a day
Trial: NCT03571126
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Placebos (Days1-4)
Trial: NCT00808119
Drug: RTI-336 (CTDP 31862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
Trial: NCT02608125
Drug: PRN1371
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01844427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01197794
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1981 twice daily
Trial: NCT01197794
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1981 once daily
Trial: NCT01197794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match AZD1981
Trial: NCT00434278
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg inhalation dose twice daily for 14±2 days
Trial: NCT00043004
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00043004
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00043004
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02667730
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500 mg four times daily for 7 days
Trial: NCT02667730
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 500mg twice daily for 7 days
Trial: NCT02667730
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib 100mg twice daily
Trial: NCT02615262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride
Trial: NCT01313039
Drug: AZ6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
Trial: NCT01529450
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800-mg (4 200-mg capsules/day) capsule
Trial: NCT02399709
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02399709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00944801
Drug: Pegylated Liposomal Doxorubicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
Trial: NCT01914939
Drug: placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00331084
Drug: antibiotic/steroid combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gtt, 4x/day, 15 days
Trial: NCT00648362
Drug: Amaryl® Tablets 1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg, single dose fasting
Trial: NCT02963766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03956550
Drug: REGN5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Dose every 4 weeks (Q4W)
Trial: NCT03956550
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Dose every 4 weeks (QW4)
Trial: NCT04198480
Drug: JMT103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg subcutaneously (SC) every 4 weeks with a loading dose of 2 mg/kg SC on study days 8 and 15.
Trial: NCT00237497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching tablets, orally, once daily for up to 28 nights.
Trial: NCT00318799
Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
Trial: NCT02822898
Drug: NaCl 0.9% in Glucose 5% with 40mEq Potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
Trial: NCT02822898
Drug: Glucion 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
Trial: NCT00440284
Drug: conventional vs. flexible, intensive insulin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02186405
Drug: LEVOTHYROXINE
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of levothyroxine
Trial: NCT03315507
Drug: PB1046 Subcutaneous Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight weekly doses of PB1046.
Trial: NCT03366974
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg bid
Trial: NCT01466127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched nasal spray placebo
Trial: NCT00767299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO, 24 weeks
Trial: NCT02128724
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.
Trial: NCT03435276
Drug: AZD9977
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3
Trial: NCT00348491
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03021590
Drug: Clarithromycin 500Mg Oral Tablet
RxNorm normalized name: Clarithromycin 500mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1000 mg Tablets every 12 hours , Esomeprazole 20 mg Capsule days all~,Clarithromycin 500 mg Tablets and Tinidazole 500 mg Tablets every 12 hours for 14 days all by mouth
Trial: NCT00678795
Drug: Sativex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours
Trial: NCT00678795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
Trial: NCT04107805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01304394
Drug: Ped3CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
Trial: NCT01852604
Drug: TMC647055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC647055 will be supplied as 150 mg oral capsules.
Trial: NCT02802930
Drug: SPF 50 Y65 110 (BAY987519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
Trial: NCT02802930
Drug: SPF 50 Y51 002 (BAY987519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
Trial: NCT02802930
Drug: SPF 15 V27 104 (BAY987519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
Trial: NCT03661125
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.
Trial: NCT02031939
Drug: Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All rectal cancer patients in this group will receive induction, gap chemotherapy (capecitabine combined with oxaliplatin) alone with chemoradiotherapy (capecitabine combine with oxaliplatin) before surgery.
Trial: NCT00986440
Drug: CS-7017
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-7017
Trial: NCT00986440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00080496
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003000
Drug: fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01574261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for four months
Trial: NCT01574261
Drug: Inositol
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol 4g/die for four months
Trial: NCT03506113
Drug: Guidelines-based antibiotics choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to IDSA/ATS guidelines
Trial: NCT03494296
Drug: patients received D-COP regimen chemotherapy
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients received D-COP regimen chemotherapy
Trial: NCT02286999
Drug: B. infantis
RxNorm normalized name: L. crispatus,gasseri,jensenii,rhamnosus/B. infantis 6 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
Trial: NCT02286999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01934829
Drug: urea-based cream
RxNorm normalized name: Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .~BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator.
Trial: NCT00796224
Drug: 60 mg/kg azithromycin ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects taken 60 mg/kg azithromycin ER
Trial: NCT00796224
Drug: 30 mg/kg azithromycin IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects taken 30 mg/kg azithromycin IR (Immediate Release)
Trial: NCT01786434
Drug: Fentanyl on-demand arm
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
Trial: NCT00404794
Drug: prednisolone and mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00404794
Drug: prednisolone and tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01860833
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: time of treatment 14 days
Trial: NCT01860833
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: time of treatment 14 days
Trial: NCT01860833
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: time of treatment 14 days
Trial: NCT01069094
Drug: Progenta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg, administered as a once daily oral dose for 90 days.
Trial: NCT01069094
Drug: Progenta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg, administered as a once daily oral dose for 90 days.
Trial: NCT01069094
Drug: Progenta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg, administered as a once daily oral dose for 90 days.
Trial: NCT01069094
Drug: Lucron Depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg IM monthly
Trial: NCT01069094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a once daily oral dose for 90 days.
Trial: NCT02050828
Drug: AKB-9778
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02652546
Drug: Effect of drug on viral load
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
Trial: NCT02652546
Drug: Effect of drug on inflammatory biomarkers
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-\^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
Trial: NCT02958085
Drug: NNC0174-0833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses of NNC0174-0833, dosed either once daily or once weekly
Trial: NCT02958085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed either once daily or once weekly
Trial: NCT00740584
Drug: 3% SPL7013 Gel (VivaGel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.
Trial: NCT00012207
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03513276
Drug: Adrenaline 10mcg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02443155
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
Trial: NCT02220530
Drug: Conscious sedation with iv midazolam and fentanyl.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
Trial: NCT01807611
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV.
Trial: NCT01376388
Drug: GSK573719/GW642444 Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
Trial: NCT02870153
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
Trial: NCT02754011
Drug: Combination of ribociclib + capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
Trial: NCT01060722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous dose of placebo material
Trial: NCT02779530
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg po, b.i.d for 6 days
Trial: NCT03537651
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination tablet for oral administration.
Trial: NCT04104607
Drug: CC-1, PSMAxCD3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation